Abstract:Alzheimer's disease (AD) progresses through a lengthy asymptomatic period during which pathological changes accumulate prior to development of clinical symptoms. As disease-modifying treatments are developed, tools to stratify risk of clinical disease will be required to guide their use. In this study, we examine the relationship of AD biomarkers in healthy middle-aged individuals to health history, family history, and neuropsychological measures and identify cerebrospinal fluid (CSF) biomarkers to stratify risk of progression from asymptomatic to symptomatic AD. CSF from cognitively normal (CN) individuals (N=1149) in the Emory Healthy Brain Study were assayed for Aβ42, total Tau (tTau), and phospho181-Tau (pTau), and a subset of 134 cognitively normal, but biomarker-positive, individuals were identified with asymptomatic AD (AsymAD) based on a locally-determined cutoff value for ratio of tTau to Aβ42. These AsymAD cases were matched for demographic features with 134 biomarker-negative controls (CN/BM-) and compared for differences in medical comorbidities and family history. Dyslipidemia emerged as a distinguishing feature between AsymAD and CN/BM-groups with significant association with personal and family history of dyslipidemia. A weaker relationship was seen with diabetes, but there was no association with hypertension. Examination of the full cohort by median regression revealed a significant relationship of CSF Aβ42 (but not tTau or pTau) with dyslipidemia and diabetes. On neuropsychological tests, CSF Aβ42 was not correlated with performance on any measures, but tTau and pTau were strongly correlated with visuospatial perception and visual episodic memory. In addition to traditional CSF AD biomarkers, a panel of AD biomarker peptides derived from integrating brain and CSF proteomes were evaluated using machine learning strategies to identify a set of 8 peptides that accurately classified CN/BM- and symptomatic AD CSF samples with AUC of 0.982. Using these 8 peptides in a low dimensional t-distributed Stochastic Neighbor Embedding analysis and k-Nearest Neighbor (k=5) algorithm, AsymAD cases were stratified into "Control-like" and "AD-like" subgroups based on their proximity to CN/BM- or AD CSF profiles. Independent analysis of these cases using a Joint Mutual Information algorithm selected a set of 5 peptides with 81% accuracy in stratifying cases into AD-like and Control-like subgroups. Performance of both sets of peptides was evaluated and validated in an independent data set from the Alzheimer's Disease Neuroimaging Initiative. Based on our findings, we conclude that there is an important role of lipid metabolism in asymptomatic stages of AD. Visuospatial perception and visual episodic memory may be more sensitive than language-based abilities to earliest stages of cognitive decline in AD. Finally, candidate CSF peptides show promise as next generation biomarkers for predicting progression from asymptomatic to symptomatic stages of AD.

Correlates of neuroimaging biomarkers in a middle‐age racially diverse cohort: Updates from the association between cardiovascular risk and preclinical Alzheimer’s Disease pathology (ASCEND) study

RACE MODIFIES THE RELATIONSHIP BETWEEN ALZHEIMER’S DISEASE (AD) BIOMARKERS AND COGNITION IN A COHORT OF MIDDLE-AGED INDIVIDUALS AT HIGH-RISK FOR AD

sPDGFRβ and neuroinflammation are associated with AD biomarkers and differ by race: The ASCEND Study

Baseline Results: the Association Between Cardiovascular Risk and Preclinical Alzheimer's Disease Pathology (ASCEND) Study.

Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort

Neuroimaging and biofluid biomarkers across race and ethnicity in older adults across the spectrum of cognition

Association of Plasma and Cerebrospinal Fluid Alzheimer Disease Biomarkers With Race and the Role of Genetic Ancestry, Vascular Comorbidities, and Neighborhood Factors

Two Year Cognitive and Biomarker Change in a Racially Diverse, Middle‐aged, Cohort at Risk for Alzheimer’s Disease

Socioeconomic Status Mediates Racial Differences Seen Using the AT(N) Framework

Relationship Between Platelet Derived Growth Factor Receptor‐β and Alzheimer’s Biomarkers in a Racially Diverse, High‐risk Cohort

Risk of Alzheimer's disease is associated with longitudinal changes in plasma biomarkers in the multi‐ethnic Washington Heights–Hamilton Heights–Inwood Columbia Aging Project (WHICAP) cohort

Effects of Vascular Risk Factors on the Association of Blood-Based Biomarkers with Alzheimer's Disease

Navigating complexities of racial disparities in Alzheimer disease biomarkers

Associations among plasma, MRI, and amyloid PET biomarkers of Alzheimer's disease and related dementias and the impact of health‐related comorbidities in a community‐dwelling cohort

Complex relationships of socioeconomic status with vascular and Alzheimer's pathways on cognition

Baseline levels and longitudinal rates of change in plasma Aβ42/40 among self-identified Black/African American and White individuals

Baseline levels and longitudinal changes in plasma Aβ42/40 among Black and white individuals

ASSOCIATIONS BETWEEN CLINICAL FUNCTIONING AND AD BIOMARKERS AMONG HISPANIC AND WHITE NON-HISPANIC OLDER ADULTS

Changes in Alzheimer Disease Blood Biomarkers and Associations With Incident All-Cause Dementia

Examination of race and gender differences in predictors of neuropsychological decline and development of Alzheimer’s disease

Predictors of Cognitive Decline in Healthy Middle-Aged Individuals with Asymptomatic Alzheimer’s Disease